Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 20;8(2):e0065122.
doi: 10.1128/msphere.00651-22. Epub 2023 Mar 6.

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals

Affiliations

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals

María Fernanda Mojica et al. mSphere. .

Abstract

Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (blaOXA-50-like), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms.

Keywords: Enterobacterales; Latin America; Pseudomonas aeruginosa; antimicrobial resistance; ceftazidime/avibactam.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. C.P. and M.V.V. have received consulting fees and/or research grants from Merck Sharp and Dohme, Pfizer, WEST, and bioMérieux. All other authors declare no competing interests.

Figures

FIG 1
FIG 1
Genetic resistance determinants of CZA-resistant P. aeruginosa isolates. Blue squares represent the presence of the respective antibiotic resistance gene, and blank represents its absence. The phylogenetic tree was obtained by canonical wgMLST using the web server cano-wgMLST_BacCompare (25) and drawn using the iTOL tool (50). ST, sequence type. New ST are indicated by *.

References

    1. Wang Y, Wang J, Wang R, Cai Y. 2020. Resistance to ceftazidime–avibactam and underlying mechanisms. J Glob Antimicrob Resist 22:18–27. doi:10.1016/j.jgar.2019.12.009. - DOI - PubMed
    1. Oliver A, Mulet X, López-Causapé C, Juan C. 2015. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21–22:41–59. doi:10.1016/j.drup.2015.08.002. - DOI - PubMed
    1. Patel G, Bonomo RA. 2013. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol 4:1–17. doi:10.3389/fmicb.2013.00048. - DOI - PMC - PubMed
    1. Logan LK, Weinstein RA. 2017. The epidemiology of Carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215:S28–S36. doi:10.1093/infdis/jiw282. - DOI - PMC - PubMed
    1. Glen KA, Lamont IL. 2021. β-lactam resistance in Pseudomonas aeruginosa: current status, future prospects. Pathogens 10. doi:10.3390/pathogens10121638. - DOI - PMC - PubMed

Publication types

LinkOut - more resources